IDH2 and glioblastoma: Despite the fact that glioblastomas are heterogeneous, the IDH1 mutation is uniformly present within a mutated tumor13, suggesting that “synthetic lethality”-based treatment approaches should affect the majority of cancer cells within IDH-mutated tumors.